INTS Intensity Tx: Enterprise Value-to-Revenue Multiple

Public company logo of Intensity Therapeutics Inc (INTS)

The virtual business model of Intensity Therapeutics (INTS), which relies on external contractors for synthesis and testing, impacts profitability. The company's enterprise value to revenue (EV/Revenue) valuation on GURU.Markets reflects the asset's dynamics, where 0.00 marks a new level. Risks are associated with the complexity of tumor injections; however, a stable R&D workforce and the hiring of specialized managers support growth potential.

Company Value to Revenue: Intensity Tx (INTS) for 11/23/2025 - 11/20/2026

Intensity Tx - analytical breakdowns and key metrics (INTS)

- share price and consensus valuation forecast:
Initial company analysis:Intensity Therapeutics Inc INTS
Product sample of Intensity Therapeutics Inc

The efficacy of the INT230-6 therapy directly impacts the capitalization of Intensity Therapeutics (INTS), shaping market expectations for its revenue. By analyzing the enterprise value-to-revenue multiple, an investor assesses the total business (EV) net of debt, which allows for the removal of leverage's influence on the fundamental value of sales. Identifying sustainable price corridors on this chart helps avoid value traps and determine safe entry points.

Competitor analysis for Intensity Therapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP